Andre H. Goy, MD

Articles by Andre H. Goy, MD

Inside the Clinic: JTCC Experts Discuss Retreatment With CAR T-Cell Therapy

ByLori A. Leslie, MD,Andre H. Goy, MD

March 10th 2022

Lori A. Leslie, MD, and Andre H. Goy, MD, discuss retreatment with CAR T-cell therapy.

Inside the Clinic: JTCC Experts Highlight Next Steps With CAR T-Cell Therapy

ByLori A. Leslie, MD,Andre H. Goy, MD

March 9th 2022

Lori A. Leslie, MD, and Andre H. Goy, MD, discuss next steps with CAR T-cell therapy.

Dr. Goy on the Utility of Axi-Cel and Brexu-Cel in Relapsed/Refractory Non-Hodgkin Lymphoma

ByAndre H. Goy, MD

January 10th 2022

Andre H. Goy, MD, discusses the clinical data reported with axicabtagene ciloleucel in patients with relapsed or refractory indolent non-Hodgkin lymphoma and real-world findings with brexucabtagene autoleucel in mantle cell lymphoma.

Dr. Goy on the Clinical Implications of CAR T-Cell Therapy in MCL

ByAndre H. Goy, MD,Andre Goy, MD, John Theurer Cancer Center

April 8th 2021

Andre Goy, MD, discusses the clinical implications of CAR T-cell therapy in mantle cell lymphoma.

Dr. Goy on the Potential Utility of BTK Inhibitors as Maintenance in MCL

ByAndre H. Goy, MD

May 10th 2020

Andre H. Goy, MD, discusses the potential utility of BTK inhibitors as maintenance therapy in mantle cell lymphoma.

Andre H. Goy, MD

Articles by Andre H. Goy, MD

Inside the Clinic: JTCC Experts Discuss Retreatment With CAR T-Cell Therapy

Inside the Clinic: JTCC Experts Highlight Next Steps With CAR T-Cell Therapy

Dr. Goy on the Utility of Axi-Cel and Brexu-Cel in Relapsed/Refractory Non-Hodgkin Lymphoma

Dr. Goy on the Clinical Implications of CAR T-Cell Therapy in MCL

Dr. Goy on the Potential Utility of BTK Inhibitors as Maintenance in MCL

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma

Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer

Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies